Biomarkers in heart failure: ST2

Antoni Bayes-Genis, Josep Lupón

Producció científica: Capítol de llibreCapítolRecercaAvaluat per experts

1 Citació (Scopus)

Resum

© Springer International Publishing Switzerland 2016. Biomarkers have emerged as indispensable tools for diagnosis and prognosis in a variety of cardiovascular diseases, and several are now considered standard of care. New markers are constantly being developed, but very few are able to signifi- cantly improve upon already-established markers. ST2 is a marker of cardiomyocyte stress and fibrosis which provides incremental value to natriuretic peptides for risk stratification in heart failure. Based upon the totality of data, measurement of ST2 is now recommended for additive risk stratification in patients with acute or ambulatory heart failure in the 2013 ACCF/AHA Guidelines. Looking forward, ST2 levels may be useful for tailoring medical therapy and to predict ventricular reverse remodeling. This chapter provides an up-to-date overview of ST2 as a marker of heart failure, and provides illustrative clinical cases into the application of ST2 now and in the future.
Idioma originalAnglès
Títol de la publicacióCardiac Biomarkers: Case Studies and Clinical Correlations
Pàgines251-268
Nombre de pàgines17
DOIs
Estat de la publicacióPublicada - 1 de gen. 2016

Fingerprint

Navegar pels temes de recerca de 'Biomarkers in heart failure: ST2'. Junts formen un fingerprint únic.

Com citar-ho